FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome

Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical immunology 2023-04, Vol.43 (3), p.662-669
Hauptverfasser: Wyatt, Rebecca C., Olek, Sven, De Franco, Elisa, Samans, Bjoern, Patel, Kashyap, Houghton, Jayne, Walter, Steffi, Schulze, Janika, Bacchetta, Rosa, Hattersley, Andrew T., Flanagan, Sarah E., Johnson, Matthew B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 669
container_issue 3
container_start_page 662
container_title Journal of clinical immunology
container_volume 43
creator Wyatt, Rebecca C.
Olek, Sven
De Franco, Elisa
Samans, Bjoern
Patel, Kashyap
Houghton, Jayne
Walter, Steffi
Schulze, Janika
Bacchetta, Rosa
Hattersley, Andrew T.
Flanagan, Sarah E.
Johnson, Matthew B.
description Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogeneous phenotype and variable immunological abnormalities. The number of cells with demethylation at the Treg cell-specific demethylated region (TSDR) is an independent biomarker of IPEX. We aimed to investigate if diagnosing IPEX at presentation with isolated diabetes could allow for effective monitoring of disease progression and assess whether TSDR analysis can aid FOXP3 variant classification and predict disease course. We describe a large genetically diagnosed IPEX cohort ( n  = 65) and 13 individuals with other monogenic autoimmunity subtypes in whom we quantified the proportion of cells with FOXP3 TSDR demethylation, normalized to the number with CD4 demethylation (%TSDR/CD4) and compare them to 29 unaffected controls. IPEX patients presenting with isolated diabetes (50/65, 77%) often later developed enteropathy (20/50, 40%) with a median interval of 23.5 weeks. %TSDR/CD4 was a good discriminator of IPEX vs. unaffected controls (ROC-AUC 0.81, median 13.6% vs. 8.5%, p  
doi_str_mv 10.1007/s10875-022-01428-w
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9957900</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2761179188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d226676813a980adf0e799579497cbe7f77f583090c069066f0e3bc6c01a6fc33</originalsourceid><addsrcrecordid>eNp9kU1PJCEQhonZjc6O_gEPG5K9eGktYBqayyZm1NXEjcav6IkwND2L6QaFbo3_XnT8Wg-eSOp96q0qXoTWCWwSALGVCFSiLIDSAsiEVsX9EhqRUrCClpJ-QyOgghQySyvoR0rXAMA4LZfRCuMcgJQwQld7R5fHDJ-d7pzgv1anIdrO-h5Pw9DWeDsll3p8oaPTT8VW50LjjO5d8Fj7Gu84PfchUzg0-OB49xKfPvg6hs6uou-NbpNde3nH6Hxv92y6Xxwe_TmYbh8WZiImfVFTyrngFWFaVqDrBqyQshRyIoWZWdEI0ZQVAwkGuATOM8BmhhsgmjeGsTH6vfC9GWadrU3ePupW3UTX6figgnbqf8W7f2oe7tTzlPwlY7TxYhDD7WBTrzqXjG1b7W0YkqKCEyIkqaqM_vqEXoch-nxepkT2owJopuiCMjGkFG3ztgwB9ZScWiSncnLqOTl1n5t-fjzjreU1qgywBZCy5Oc2vs_-wvYR50GjVw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779572702</pqid></control><display><type>article</type><title>FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Wyatt, Rebecca C. ; Olek, Sven ; De Franco, Elisa ; Samans, Bjoern ; Patel, Kashyap ; Houghton, Jayne ; Walter, Steffi ; Schulze, Janika ; Bacchetta, Rosa ; Hattersley, Andrew T. ; Flanagan, Sarah E. ; Johnson, Matthew B.</creator><creatorcontrib>Wyatt, Rebecca C. ; Olek, Sven ; De Franco, Elisa ; Samans, Bjoern ; Patel, Kashyap ; Houghton, Jayne ; Walter, Steffi ; Schulze, Janika ; Bacchetta, Rosa ; Hattersley, Andrew T. ; Flanagan, Sarah E. ; Johnson, Matthew B.</creatorcontrib><description>Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogeneous phenotype and variable immunological abnormalities. The number of cells with demethylation at the Treg cell-specific demethylated region (TSDR) is an independent biomarker of IPEX. We aimed to investigate if diagnosing IPEX at presentation with isolated diabetes could allow for effective monitoring of disease progression and assess whether TSDR analysis can aid FOXP3 variant classification and predict disease course. We describe a large genetically diagnosed IPEX cohort ( n  = 65) and 13 individuals with other monogenic autoimmunity subtypes in whom we quantified the proportion of cells with FOXP3 TSDR demethylation, normalized to the number with CD4 demethylation (%TSDR/CD4) and compare them to 29 unaffected controls. IPEX patients presenting with isolated diabetes (50/65, 77%) often later developed enteropathy (20/50, 40%) with a median interval of 23.5 weeks. %TSDR/CD4 was a good discriminator of IPEX vs. unaffected controls (ROC-AUC 0.81, median 13.6% vs. 8.5%, p  &lt; 0.0001) with higher levels of demethylation associated with more severe disease. Patients with other monogenic autoimmunity had a similar %TSDR/CD4 to controls (median 8.7%, p  = 1.0). Identifying increased %TSDR/CD4 in patients with novel FOXP3 mutations presenting with isolated diabetes facilitates diagnosis and could offer an opportunity to monitor patients and begin immune modulatory treatment before onset of severe enteropathy.</description><identifier>ISSN: 0271-9142</identifier><identifier>ISSN: 1573-2592</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-022-01428-w</identifier><identifier>PMID: 36600150</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Autoimmune diseases ; Autoimmunity ; Biomedical and Life Sciences ; Biomedicine ; CD4 antigen ; Demethylation ; Diabetes ; Diabetes Mellitus ; Diagnosis ; Diarrhea ; Forkhead Transcription Factors - genetics ; Foxp3 protein ; Genetic Diseases, X-Linked - genetics ; Humans ; Immunology ; Infectious Diseases ; Internal Medicine ; Lymphocytes T ; Medical Microbiology ; Mutation ; Original ; Original Article ; Pathogenicity ; Phenotypes ; T-Lymphocytes, Regulatory</subject><ispartof>Journal of clinical immunology, 2023-04, Vol.43 (3), p.662-669</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d226676813a980adf0e799579497cbe7f77f583090c069066f0e3bc6c01a6fc33</citedby><cites>FETCH-LOGICAL-c474t-d226676813a980adf0e799579497cbe7f77f583090c069066f0e3bc6c01a6fc33</cites><orcidid>0000-0002-6519-6687</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-022-01428-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-022-01428-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36600150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wyatt, Rebecca C.</creatorcontrib><creatorcontrib>Olek, Sven</creatorcontrib><creatorcontrib>De Franco, Elisa</creatorcontrib><creatorcontrib>Samans, Bjoern</creatorcontrib><creatorcontrib>Patel, Kashyap</creatorcontrib><creatorcontrib>Houghton, Jayne</creatorcontrib><creatorcontrib>Walter, Steffi</creatorcontrib><creatorcontrib>Schulze, Janika</creatorcontrib><creatorcontrib>Bacchetta, Rosa</creatorcontrib><creatorcontrib>Hattersley, Andrew T.</creatorcontrib><creatorcontrib>Flanagan, Sarah E.</creatorcontrib><creatorcontrib>Johnson, Matthew B.</creatorcontrib><title>FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><addtitle>J Clin Immunol</addtitle><description>Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogeneous phenotype and variable immunological abnormalities. The number of cells with demethylation at the Treg cell-specific demethylated region (TSDR) is an independent biomarker of IPEX. We aimed to investigate if diagnosing IPEX at presentation with isolated diabetes could allow for effective monitoring of disease progression and assess whether TSDR analysis can aid FOXP3 variant classification and predict disease course. We describe a large genetically diagnosed IPEX cohort ( n  = 65) and 13 individuals with other monogenic autoimmunity subtypes in whom we quantified the proportion of cells with FOXP3 TSDR demethylation, normalized to the number with CD4 demethylation (%TSDR/CD4) and compare them to 29 unaffected controls. IPEX patients presenting with isolated diabetes (50/65, 77%) often later developed enteropathy (20/50, 40%) with a median interval of 23.5 weeks. %TSDR/CD4 was a good discriminator of IPEX vs. unaffected controls (ROC-AUC 0.81, median 13.6% vs. 8.5%, p  &lt; 0.0001) with higher levels of demethylation associated with more severe disease. Patients with other monogenic autoimmunity had a similar %TSDR/CD4 to controls (median 8.7%, p  = 1.0). Identifying increased %TSDR/CD4 in patients with novel FOXP3 mutations presenting with isolated diabetes facilitates diagnosis and could offer an opportunity to monitor patients and begin immune modulatory treatment before onset of severe enteropathy.</description><subject>Autoimmune diseases</subject><subject>Autoimmunity</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>CD4 antigen</subject><subject>Demethylation</subject><subject>Diabetes</subject><subject>Diabetes Mellitus</subject><subject>Diagnosis</subject><subject>Diarrhea</subject><subject>Forkhead Transcription Factors - genetics</subject><subject>Foxp3 protein</subject><subject>Genetic Diseases, X-Linked - genetics</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Lymphocytes T</subject><subject>Medical Microbiology</subject><subject>Mutation</subject><subject>Original</subject><subject>Original Article</subject><subject>Pathogenicity</subject><subject>Phenotypes</subject><subject>T-Lymphocytes, Regulatory</subject><issn>0271-9142</issn><issn>1573-2592</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1PJCEQhonZjc6O_gEPG5K9eGktYBqayyZm1NXEjcav6IkwND2L6QaFbo3_XnT8Wg-eSOp96q0qXoTWCWwSALGVCFSiLIDSAsiEVsX9EhqRUrCClpJ-QyOgghQySyvoR0rXAMA4LZfRCuMcgJQwQld7R5fHDJ-d7pzgv1anIdrO-h5Pw9DWeDsll3p8oaPTT8VW50LjjO5d8Fj7Gu84PfchUzg0-OB49xKfPvg6hs6uou-NbpNde3nH6Hxv92y6Xxwe_TmYbh8WZiImfVFTyrngFWFaVqDrBqyQshRyIoWZWdEI0ZQVAwkGuATOM8BmhhsgmjeGsTH6vfC9GWadrU3ePupW3UTX6figgnbqf8W7f2oe7tTzlPwlY7TxYhDD7WBTrzqXjG1b7W0YkqKCEyIkqaqM_vqEXoch-nxepkT2owJopuiCMjGkFG3ztgwB9ZScWiSncnLqOTl1n5t-fjzjreU1qgywBZCy5Oc2vs_-wvYR50GjVw</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Wyatt, Rebecca C.</creator><creator>Olek, Sven</creator><creator>De Franco, Elisa</creator><creator>Samans, Bjoern</creator><creator>Patel, Kashyap</creator><creator>Houghton, Jayne</creator><creator>Walter, Steffi</creator><creator>Schulze, Janika</creator><creator>Bacchetta, Rosa</creator><creator>Hattersley, Andrew T.</creator><creator>Flanagan, Sarah E.</creator><creator>Johnson, Matthew B.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6519-6687</orcidid></search><sort><creationdate>20230401</creationdate><title>FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome</title><author>Wyatt, Rebecca C. ; Olek, Sven ; De Franco, Elisa ; Samans, Bjoern ; Patel, Kashyap ; Houghton, Jayne ; Walter, Steffi ; Schulze, Janika ; Bacchetta, Rosa ; Hattersley, Andrew T. ; Flanagan, Sarah E. ; Johnson, Matthew B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d226676813a980adf0e799579497cbe7f77f583090c069066f0e3bc6c01a6fc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autoimmune diseases</topic><topic>Autoimmunity</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>CD4 antigen</topic><topic>Demethylation</topic><topic>Diabetes</topic><topic>Diabetes Mellitus</topic><topic>Diagnosis</topic><topic>Diarrhea</topic><topic>Forkhead Transcription Factors - genetics</topic><topic>Foxp3 protein</topic><topic>Genetic Diseases, X-Linked - genetics</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Lymphocytes T</topic><topic>Medical Microbiology</topic><topic>Mutation</topic><topic>Original</topic><topic>Original Article</topic><topic>Pathogenicity</topic><topic>Phenotypes</topic><topic>T-Lymphocytes, Regulatory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wyatt, Rebecca C.</creatorcontrib><creatorcontrib>Olek, Sven</creatorcontrib><creatorcontrib>De Franco, Elisa</creatorcontrib><creatorcontrib>Samans, Bjoern</creatorcontrib><creatorcontrib>Patel, Kashyap</creatorcontrib><creatorcontrib>Houghton, Jayne</creatorcontrib><creatorcontrib>Walter, Steffi</creatorcontrib><creatorcontrib>Schulze, Janika</creatorcontrib><creatorcontrib>Bacchetta, Rosa</creatorcontrib><creatorcontrib>Hattersley, Andrew T.</creatorcontrib><creatorcontrib>Flanagan, Sarah E.</creatorcontrib><creatorcontrib>Johnson, Matthew B.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wyatt, Rebecca C.</au><au>Olek, Sven</au><au>De Franco, Elisa</au><au>Samans, Bjoern</au><au>Patel, Kashyap</au><au>Houghton, Jayne</au><au>Walter, Steffi</au><au>Schulze, Janika</au><au>Bacchetta, Rosa</au><au>Hattersley, Andrew T.</au><au>Flanagan, Sarah E.</au><au>Johnson, Matthew B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><addtitle>J Clin Immunol</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>43</volume><issue>3</issue><spage>662</spage><epage>669</epage><pages>662-669</pages><issn>0271-9142</issn><issn>1573-2592</issn><eissn>1573-2592</eissn><abstract>Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogeneous phenotype and variable immunological abnormalities. The number of cells with demethylation at the Treg cell-specific demethylated region (TSDR) is an independent biomarker of IPEX. We aimed to investigate if diagnosing IPEX at presentation with isolated diabetes could allow for effective monitoring of disease progression and assess whether TSDR analysis can aid FOXP3 variant classification and predict disease course. We describe a large genetically diagnosed IPEX cohort ( n  = 65) and 13 individuals with other monogenic autoimmunity subtypes in whom we quantified the proportion of cells with FOXP3 TSDR demethylation, normalized to the number with CD4 demethylation (%TSDR/CD4) and compare them to 29 unaffected controls. IPEX patients presenting with isolated diabetes (50/65, 77%) often later developed enteropathy (20/50, 40%) with a median interval of 23.5 weeks. %TSDR/CD4 was a good discriminator of IPEX vs. unaffected controls (ROC-AUC 0.81, median 13.6% vs. 8.5%, p  &lt; 0.0001) with higher levels of demethylation associated with more severe disease. Patients with other monogenic autoimmunity had a similar %TSDR/CD4 to controls (median 8.7%, p  = 1.0). Identifying increased %TSDR/CD4 in patients with novel FOXP3 mutations presenting with isolated diabetes facilitates diagnosis and could offer an opportunity to monitor patients and begin immune modulatory treatment before onset of severe enteropathy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36600150</pmid><doi>10.1007/s10875-022-01428-w</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6519-6687</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0271-9142
ispartof Journal of clinical immunology, 2023-04, Vol.43 (3), p.662-669
issn 0271-9142
1573-2592
1573-2592
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9957900
source MEDLINE; SpringerLink Journals
subjects Autoimmune diseases
Autoimmunity
Biomedical and Life Sciences
Biomedicine
CD4 antigen
Demethylation
Diabetes
Diabetes Mellitus
Diagnosis
Diarrhea
Forkhead Transcription Factors - genetics
Foxp3 protein
Genetic Diseases, X-Linked - genetics
Humans
Immunology
Infectious Diseases
Internal Medicine
Lymphocytes T
Medical Microbiology
Mutation
Original
Original Article
Pathogenicity
Phenotypes
T-Lymphocytes, Regulatory
title FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FOXP3%20TSDR%20Measurement%20Could%20Assist%20Variant%20Classification%20and%20Diagnosis%20of%20IPEX%20Syndrome&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Wyatt,%20Rebecca%20C.&rft.date=2023-04-01&rft.volume=43&rft.issue=3&rft.spage=662&rft.epage=669&rft.pages=662-669&rft.issn=0271-9142&rft.eissn=1573-2592&rft_id=info:doi/10.1007/s10875-022-01428-w&rft_dat=%3Cproquest_pubme%3E2761179188%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779572702&rft_id=info:pmid/36600150&rfr_iscdi=true